

**Louisiana Department of Health  
Medicaid Pharmaceutical and Therapeutics Committee  
TOP\$ Virtual Review  
Via Videoconferencing  
November 3, 2021  
9:00 AM  
DRAFT**

- I. Call to Order.....Marty McKay
- II. Parliamentary Business .....Marty McKay
  - A. Introduction of Members/Roll Call
- III. P & T Committee Review Virtual Process.....Hind Douiki/Melwyn Wendt
- IV. Reports.....Melwyn Wendt
  - A. PDL Reflecting Spring 2021 Recommendations
- V. New Business.....Hind Douiki
  - A. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
    - 1. Alzheimer’s Agents
    - 2. Anthelmintics - New
    - 3. Anti-Allergens, Oral - New
    - 4. Anticonvulsants
    - 5. Antidepressants, Other
    - 6. Antidepressants, SSRIs
    - 7. Antihistamines, Minimally Sedating
    - 8. Antihypertensives, Sympatholytics
    - 9. Antihyperuricemics
    - 10. Antiparkinson’s Agents
    - 11. Antipsoriatics, Oral
    - 12. Antipsoriatics, Topical
    - 13. Antipsychotics
    - 14. Anxiolytics
    - 15. Bile Salts
    - 16. Bronchodilators, Beta Agonist
    - 17. Colony Stimulating Factors
    - 18. COPD Agents
    - 19. Cytokine and CAM Antagonists
    - 20. Emollients
    - 21. Enzyme Replacement, Gauchers Disease - New
    - 22. Epinephrine, Self-Injected
    - 23. Erythropoiesis Stimulating Proteins
    - 24. Glucocorticoids, Inhaled
    - 25. Glucocorticoids, Oral
    - 26. Hemophilia Treatment

27. Histamine II Receptor Blocker
28. Idiopathic Pulmonary Fibrosis – New
29. Immune Globulins – New
30. Immunomodulators, Asthma – New
31. Immunomodulators, Atopic Dermatitis
32. Immunomodulators, Lupus - New
33. Immunomodulators, Topical
34. Intranasal Rhinitis Agents
35. Leukotriene Modifiers
36. Methotrexate
37. Movement Disorders
38. Neuropathic Pain
39. NSAIDs
40. Oncology Oral – Breast
41. Oncology Oral – Hematologic
42. Oncology Oral - Lung
43. Oncology Oral – Other
44. Oncology Oral – Prostate
45. Oncology Oral – Renal Cell
46. Oncology Oral - Skin
47. Ophthalmic Antibiotics
48. Ophthalmic, Antibiotic-Steroid Combinations
49. Ophthalmics for Allergic Conjunctivitis
50. Ophthalmics, Anti-Inflammatory
51. Ophthalmics, Anti-Inflammatory/ Immunomodulator
52. Ophthalmics, Cystinosis - New
53. Ophthalmics, Glaucoma Agents
54. Otic Antibiotics
55. Otic Anti-Infectives & Anesthetics
56. Progestational Agents
57. Sedative Hypnotics
58. Sickle Cell Anemia Treatments - New
59. Smoking Cessation
60. Steroids, Topical High
61. Steroids, Topical Low
62. Steroids, Topical Medium
63. Steroids, Topical Very High
64. Stimulants and Related Agents
65. Thrombopoiesis Stimulating Proteins

VI. New & Other Single Drug Reviews.....Hind Douiki

66. Antifungals, Oral - Brexafemme<sup>®</sup>
67. Bladder Relaxant Preparations – Myrbetriq<sup>®</sup> Granules
68. Glucagon Agents – Zegalogue<sup>®</sup> Syringe
69. Glucagon Agents – Zegalogue<sup>®</sup> Autoinjector
70. Multiple Sclerosis Agents – Ponvory<sup>®</sup> Starter Pack

- 71. Multiple Sclerosis Agents – Ponvory<sup>®</sup> Tablet
- 72. Opiate Dependence Treatments – Kloxxado<sup>®</sup> Spray
- 73. Phosphate Binders – Magnebind<sup>®</sup> 400 RX
- 74. Uterine Disorder Treatments - Myfembree<sup>®</sup>

VII. Other Business

VIII. Next Steps

A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – Friday, April 29, 2022 or Friday, May 6, 2022

X. Public Testimony